{"acquisitions":[],"changes":[],"country":"FR","description":"Clinical-stage biotech developing homeoprotein-based therapies for ALS, Parkinson's and retinal disease. Built for patients with major neurodegenerative diseases lacking disease-modifying treatments. Lead candidate BREN02 (Engrailed 1) leverages founder Alain Prochiantz's discovery that developmental homeoproteins remain active throughout life.","domain":"brainever.com","employees":null,"founded":2018,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":48.853495,"lng":2.348391,"location":"Paris, France","multiples":[],"name":"BrainEver","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":35640000,"connectionsAmong":[],"currency":"EUR","date":"2025-07-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"brainever-com-2025-07-01-growth","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"seed","url":null}],"slug":"brainever-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"brainever.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://brainever.com"},{"fact":"description","publisher":"brainever.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://brainever.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":38772000,"traction":[],"updatedAt":"2026-05-02","valuations":[]}